Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nitrate · 1 trial · 2 indications
Response to a constant jet of air applied to a hypersensitive tooth was evaluated using a 100 millimeter (mm) VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score immediately post treatment.
Response to a constant (duration, pressure, temperature, distance from target) jet of air applied to a hypersensitive tooth was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score at 10 minutes post treatment.
Response to a constant (duration, pressure, temperature, distance from target) jet of air applied to a hypersensitive tooth was evaluated using a 100 mm VAS pain response scale. According to this analog scale, pain response for stimulated tooth ranged from 0 (no pain) to 100 (intense pain). Change from baseline in pain response was calculated using VAS score at 20 minutes post treatment.
| Arm | Type | Description |
|---|---|---|
| Sterile water | PLACEBO_COMPARATOR | Participants to receive 250 microlitres (μL) of sterile water. |
| Potassium nitrate 5% solution | EXPERIMENTAL | Participants to receive 250 μL of potassium nitrate 5% solution. |
| Potassium nitrate 2.5% solution | EXPERIMENTAL | Participants to receive 250 μL of potassium nitrate 2.5% solution. |
| Name | Type | Description |
|---|---|---|
| Potassium Nitrate | DRUG | 250 μL of Potassium nitrate solution (either 5% or 2.5%) |
| Placebo | DRUG | Sterile Water |
Inclusion Criteria: * General Health and Oral Heath: Good general health and oral health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history. * Teeth: Presence of teeth in various locations in the mouth to determine stent success. Requir...
Nitrate is an investigational small molecule being developed by GSK plc for the treatment of dentin sensitivity, also known as dentinal hypersensitivity or dentin hypersensitivity. It is being studied for its ability to reduce dental pain associated with these conditions.
Nitrate is being developed by GSK plc, a pharmaceutical company traded on the London Stock Exchange under the ticker GSK. The drug is currently in clinical development for dentin sensitivity and related hypersensitivity conditions.
Nitrate is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials have been completed, but the drug remains in early-stage development for dentin hypersensitivity.
Nitrate has been studied in three completed clinical trials. NCT01587950 was a Phase 1 study with 12 participants, NCT02226562 was a Phase 2 study with 191 participants, and NCT03943095 was a Phase 2 study with 123 participants, all evaluating its effects on dentin hypersensitivity.
Nitrate is being studied in formulations that include potassium nitrate, as indicated by the clinical trial NCT01587950, which evaluated the effects of potassium nitrate in reducing dentinal hypersensitivity. However, Nitrate as a drug asset may refer to the active ingredient or the product.